Journal article

White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimer's disease

Miguel Angel Araque Caballero, Marc Suarez-Calvet, Marco Duering, Nicolai Franzmeier, Tammie Benzinger, Anne M Fagan, Randall J Bateman, Clifford R Jack, Johannes Levin, Martin Dichgans, Mathias Jucker, Celeste Karch, Colin L Masters, John C Morris, Michael Weiner, Martin Rossor, Nick C Fox, Jae-Hong Lee, Stephen Salloway, Adrian Danek Show all

BRAIN | OXFORD UNIV PRESS | Published : 2018


White matter alterations are present in the majority of patients with Alzheimer's disease type dementia. However, the spatiotemporal pattern of white matter changes preceding dementia symptoms in Alzheimer's disease remains unclear, largely due to the inherent diagnostic uncertainty in the preclinical phase and increased risk of confounding age-related vascular disease and stroke in late-onset Alzheimer's disease. In early-onset autosomal-dominantly inherited Alzheimer's disease, participants are destined to develop dementia, which provides the opportunity to assess brain changes years before the onset of symptoms, and in the absence of ageing-related vascular disease. Here, we assessed mean..

View full abstract


Awarded by ERC

Awarded by MRC Dementias Platform UK

Awarded by National Institute on Aging (NIA)


Funding Acknowledgements

The study was funded by an ERC career integration grant (PCIG12-GA-2012-334259 to M.E), and Alzheimer Forschung Initiative (to M.E.), National Institute for Health Research University College London Hospitals Biomedical Research Centre and the MRC Dementias Platform UK (MR/L023784/1 and MR/009076/1 to M.R.). Data collection and sharing for this project was supported by The Dominantly Inherited Alzheimer's Network (DIAN) funded by the National Institute on Aging (NIA, U19AG032438) and the German Center for Neurodegenerative Diseases (DZNE), Raul Carrea Institute for Neurological Research (FLENI), Partial support by the Research and Development Grants for Dementia from Japan Agency for Medical Research and Development, AMED, and the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI).